A phase 3 trial evaluates a PARP inhibitor or placebo plus an androgen pathway inhibitor to treat men with advanced prostate cancer associated with genetic changes.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/therapy-combo-improves-radiographic-pfs-prostate-cancer-2026a1000i2s?src=rss
Author :
Publish date : 2026-05-31 20:38:00
Copyright for syndicated content belongs to the linked Source.
